


A cost-effective innovation in anaemia management for paediatric haemodialysis-dependant chronic kidney disease patients

Original
Article

AIM: To establish if IV ferric carboxymaltose is a viable alternative to iron sucrose in paediatric haemodialysis patients

DESIGN & OUTCOMES: Retrospective comparative study investigating the efficacy, safety and cost-effectiveness of IV iron therapy in the management of anaemia in paediatric haemodialysis (HD)-dependant kidney failure



CONCLUSION: Ferric carboxymaltose is a safe and and cost-effective option for the management of iron deficiency anaemia and improves healthcare delivery for paediatric haemodialysis patients.

Preston et al. 2024



Pediatric Nephrology
Journal of the
International Pediatric Nephrology Association